ArticleJournal of thoracic disease2026
Myeloprotection effect of trilaciclib in lung cancer patients undergoing chemotherapy: a real-world retrospective study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemotherapy-induced myelosuppression (CIM) is a frequent complication in lung cancer, leading to treatment delays, dose reductions, and increased healthcare utilization. Trilaciclib, a first-in-class CDK4/6 inhibitor with myeloprotective properties, has been approved for extensive-stage small-cell lung cancer (ES-SCLC), but real-world evidence in broader lung cancer populations is limited. This retrospective real-world study aimed to evaluate the myeloprotection effects of trilaciclib in lung cancer patients undergoing chemotherapy. Methods: We conducted a retrospective analysis of lung cancer patients who received chemotherapy at the First Affiliated Hospital of Air Force Medical University between January 2023 and June 2024. Patients were categorized into trilaciclib group and non-trilaciclib group. Baseline characteristics, myelosuppression grades, drug dosages for myelosuppression treatment, chemotherapy delays, hospitalizations, and alopecia were collected and analyzed. Inverse probability of treatment weighting (IPTW) was applied to adjust for baseline imbalances. Results: A total of 108 patients were included (54 per group). Overall myelosuppression incidence did not differ significantly (74.1% Conclusions: In a real-world cohort of patients with locally advanced or metastatic lung cancer receiving chemotherapy, trilaciclib was associated with a lower incidence of severe myelosuppression, reduced G-CSF utilization, and fewer hospitalizations. These findings should be considered exploratory, and may support the potential role of trilaciclib as a myeloprotective strategy to optimize treatment continuity and reduce healthcare burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.